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Background: The emergence of skin substitutes provides a new approach for the
treatment of wound repair and healing. The consistent and steady release of
angiogenic factors is an important factor in the promotion of angiogenesis in skin
substitutes, which usually lack, yet need, a vascular network.
Methods: In this study, ginsenoside Rg1, a natural compound isolated from Panax
notoginseng (PNS), was incorporated into a collagen/chitosan-gelatin microsphere
(CC-GMS) scaffold. The cumulative release kinetics were evaluated, and the effects of
the released Rg1 on human umbilical vein endothelial cells (HUVECs) behavior,
including proliferation, migration, tube formation, cell-cycle progression, cell apoptosis,
and vascular endothelial growth factor (VEGF) secretion, were investigated. Additionally,
HUVECs were cultured on the CC-GMS scaffold to test its biocompatibility. Standard
Rg1 and VEGF were used as positive controls.
Results: The results indicated that the CC-GMS scaffold had good release kinetics. The
Rg1 released from the CC-GMS scaffold did not lose its activity and had a significant
effect on HUVEC proliferation. Both Rg1 and VEGF promoted HUVEC migration and
tube formation. Rg1 did not induce HUVEC apoptosis but instead promoted HUVEC
progression into the S and G2/M phases of the cell cycle. Rg1 significantly increased
VEGF secretion compared with that in the control group. HUVEC culture on the
CC-GMS scaffold indicated that this scaffold has good biocompatibility and that
CC-GMS scaffolds containing different concentrations of Rg1 promote HUVEC
attachment in a dose- and time-dependent manner.
Conclusions: Rg1 may represent a new class of angiogenic agent that can be
encapsulated in CC-GMS scaffolds to exert angiogenic effects in engineered tissue.
Keywords: Angiogenesis, Panax notoginseng saponins, Gelatin microsphere, Controlled
release, Vascular endothelial growth factor (VEGF)Background
Skin loss remains a major healthcare problem around the world, especially in develop-
ing countries [1]. As such dermal defects do not heal spontaneously, scar formation
due to full-thickness skin loss is inevitable unless skin substitutes are used [2]. The
porous collagen/chitosan (CC) scaffold-based skin tissue engineering approach has be-
come an important method for skin tissue repair and regeneration. Due to its natural
origin, this scaffold has high biocompatibility and biodegradability. Implanted CC© 2013 Zheng et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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for tissue guidance to accelerate wound healing in vivo [3,4]. However, a CC scaffold it-
self lacks normal vascular networks, and angiogenesis is slow after implantation in vivo.
This scaffold may not be sufficient to induce rapid wound angiogenesis and regener-
ation at the initial stage of wound healing [5]. To accelerate angiogenesis, a CC scaffold
could be combined with different types of microspheres as carriers for the controlled
release of growth factors or other angiogenic factors. An extraordinary number of nat-
ural (i.e., collagen, alginate, and gelatin) and synthetic (i.e., poly(glycolic acid) and poly
(L-lactic acid)) materials have been used as biomaterials in controlled-release applica-
tions [6]. Among these materials, gelatin, a natural polymer derived from collagen, is
widely used. To load different bioactive factors, variations in the electrical and physical
properties of gelatin microsphere (GMS)-based controlled-release systems can be
achieved, depending on the fabrication method [7]. The combination of a GMS con-
trolled drug delivery system with a skin tissue scaffold could be highly beneficial for
wound angiogenesis and regeneration.
Angiogenic growth factors are often used in tissue engineering. However, growth fac-
tors have short biological half-lives. Platelet-derived growth factor (PDGF), isolated
from platelets, cannot be detected in the circulation and has a half-life of less than 4 h
when injected intravenously [8]. Moreover, the method of scaffold production and the
surrounding in vivo environment may accelerate growth factor deactivation. Thus,
there are limitations to maintaining therapeutic levels of growth factors at wound sites
for healing periods of up to 2 weeks in the early period of angiogenesis.
Panax notoginseng (PNS), a well-known traditional Chinese medicine that has been
extensively used for thousands of years, has been widely used in vitro and in vivo to en-
courage angiogenesis. Ginsenosides are the major active components of PNS. Ginseno-
side Rg1, abundant in PNS, has a rigid steroidal skeleton with four transfused rings and
two sugar moieties [9]. This ginsenoside is one of the most active ingredients in PNS
and has a broad range of activities. Rg1 has estrogen-like activity and may represent a
novel class of potent phytoestrogens [10]. Estrogen is known to directly modulate
angiogenesis via effects on endothelial cells [11]. Rg1 has been demonstrated to have
beneficial effects on ischemia-induced angiogenesis [12] and to enhance endothelial
progenitor cell angiogenic potency [13]. These findings indicate the potential usefulness
of ginsenoside Rg1 in angiogenesis and regeneration in skin tissue engineering.
Controlled release of Rg1 from a porous CC-GMS scaffold may be of effect in enhan-
cing wound angiogenesis and healing. To date, there are few studies on Rg1 used in
scaffolds, and the stability and activity of Rg1 remain unknown after its release from a
CC-GMS scaffold. In this study, a porous CC-GMS scaffold for the controlled release
of Rg1 was designed for angiogenesis and regeneration in skin tissue engineering.
The Rg1 release kinetics were investigated. The activity of the released Rg1 was
characterized by measuring human umbilical vein endothelial cells (HUVECs) pro-
liferation, migration, tube formation, cell-cycle progression, apoptosis, and vascular
endothelial growth factor (VEGF) expression. The optimum Rg1 concentration was
also detected. Additionally, HUVECs were cultured on CC-GMS scaffolds to detect
the scaffolds’ biocompatibility. The purpose of this study was to develop a new
CC-GMS scaffold that can slowly release Rg1 and to evaluate the activity and sta-
bility of the released Rg1.
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Materials
Rg1 (purity > 98%) was purchased from the National Institute for the Control of
Pharmaceutical and Biological Products (NICPBP, Beijing, China). A stock solution of
Rg1 was prepared in sterile dimethyl sulfoxide (DMSO) (Sigma, Deisenhofen,
Germany). VEGF and HUVECs were purchased from Life Technologies Corporation
(Carlsbad, NM, USA). Medium 200 and Low Serum Growth Supplement (LSGS) were
purchased from Invitrogen (Carlsbad, CA, USA). Fetal bovine serum was obtained from
Gibco (Grand Island, NY, USA). An XTT Cell Proliferation Assay Kit (2, 3-bis-(2-meth-
oxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide), BD Matrigel™, a cell cycle
kit, and a cell apoptosis kit were purchased from BD Biosciences (San Diego, CA, US).
Transwell-24 well permeable supports (8.0 mm) were obtained from Corning Life Sciences.
An anti-VEGF antibody was purchased from Abcam (Cambridge, MA, USA). Goat
anti-rabbit IgG-FITC was purchased from Pierce (Rockford, IL, USA). The reagent
4′, 6-diamidino-2-phenylindole dihydrochloride (DAPI) was purchased from Sigma
(St. Louis, MO, USA).
Cell culture and seeding
HUVECs were expanded in Medium 200 supplemented with 10 ml of LSGS and used
for experiments between passages 3 and 6 to ensure the genetic stability of the culture,
according to the manufacturer’s instructions. The HUVECs were expanded in flasks in
Medium 200 and 1% penicillin/streptomycin in a humidified incubator at 37°C with 5%
CO2. Every 3–4 days, the HUVECs were passaged with 0.05% trypsin, and the medium
was changed every other day.
Preparation of CC scaffolds activated with GMSs containing Rg1/VEGF
Type A gelatin was used to fabricate GMSs following the method of emulsion-
condensation cross-linking [14]. In brief, 5 ml of a gelatin solution (10%) and 100 ml of
soybean oil (preheated to 45°C) were mixed together and stirred at 13,000 rpm for
10 min in a 45°C water bath. Ice water was then added while stirring to cool the gel-
atin solution and form microspheres. Next, the microspheres were washed with pre-
cooled acetone to remove residual soybean oil. The precipitated microspheres were
then cross-linked with a 1% glutaraldehyde solution at 37°C for 2 h, followed by the
addition of glycine (Sigma) at room temperature for 30 min. The synthetic GMSs
were washed with distilled water several times and dried at 37°C. The sizes and
shapes of the microspheres were examined under a scanning electron microscope
(SEM) (Philips XL30, Eindhoven, Netherlands). Microspheres with a diameter ran-
ging from 10–50 μm were selected by sifting through mesh. The water content of the
microspheres was calculated based on their volume variation after swelling in PBS at
room temperature. The original Rg1 and VEGF solutions were diluted with distilled
deionized water to a defined concentration. Incorporation of Rg1 or VEGF into the
GMSs was achieved by adding one of the above solutions to 2 mg of freeze-dried
GMSs and incubating for 2 h at room temperature to allow the solution to be
impregnated into the dried microspheres. The Rg1 or VEGF solution was completely
absorbed into the microspheres because the solution volume was much less than that
theoretically required for the equilibrated swelling of microspheres. As a control,
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empty GMSs.
CC-GMS scaffolds were prepared using the freezing and lyophilizing method, with
moderate modifications [15]. Briefly, type I collagen and chitosan were each dissolved
in 0.5 M acetic acid to form 0.5% (w/v) solutions that were mixed at a ratio of 9:1 (v/v).
GMSs containing different concentrations of Rg1, PBS, or VEGF were then homo-
geneously blended with the mixed solution. The cross-linking agent, a 0.1% (w/v)
glutaraldehyde solution, was added, and the mixture was injected into a 12-well
plate. The plates containing the scaffolds were frozen at −80°C overnight and then
lyophilized for 24 h to form porous CC-GMS scaffolds. The scaffolds were washed
several times with PBS and distilled water and were further treated with 75% etha-
nol before use.
The cumulative Rg1 released from the CC-GMS scaffolds in vitro was analyzed using
a UV spectrophotometer at a wavelength of 208 nm, until release stopped. Finally, the
released Rg1 was diluted to specific concentrations and then added to culture medium
for further HUVEC culture experiments.
In vitro study
The chemotactic effects of Rg1 on HUVECs were tested both for Rg1 released from
the CC-GMS scaffold and for a standard Rg1 solution.
Cell viability assessment by XTT assay
The viability of the cells was assessed by XTT assay. Briefly, HUVECs were seeded at a
density of 1 × 104 cells/well in a 96-well plate and cultured for 24 h. After cell attach-
ment, low-serum culture medium (0.5% FBS) with different doses of released Rg1
(0–100 μg/ml) or 50 μg/ml standard Rg1 were added and cultured for 24, 48, or 72 h.
Cells treated with 20 ng/ml VEGF served as positive control groups. Next, XTT solution
was added to the wells (50 μl/well). After 4 h of incubation, the absorbance was measured
with a microplate reader (Bio-Rad, Hercules, CA, USA) at 490 nm. Three duplicate wells
from at least three independent experiments were tested.
Transwell migration
The effect of Rg1 on HUVEC invasion was measured using a 6.5 mm Transwell tissue
culture insert with an 8.0 μm polycarbonate membrane and a 24-well companion plate.
The upper side of the membrane was pre-coated with 1:50 (v/v) Matrigel. In total,
2 × 104 HUVECs were resuspended in low-serum medium (200 μl) and seeded onto
the culture inserts in triplicate. The inserts were then deposited into the 24-well
companion plate along with 600 μl of low-serum medium containing different con-
centrations of released Rg1 (0–100 μg/ml), standard Rg1, or VEGF. Next, 24 h
after HUVEC seeding, the inserts were removed, fixed in 20% ethanol, and then
washed with PBS. Noninvasive cells on the upper surface of the membrane were
removed. Cells that migrated to the bottom well through the porous membrane
were stained with a 0.1% crystal violet solution for 20 min, photographed at 100 ×magni-
fication, and counted using Image-Pro Plus software (v.6.0; Media Cybernetics, Silver
Spring, MD). The percent increase in migration in each experimental group was com-
pared with migration in the control group.
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In total, 1 × 105 HUVECs were cultured in 48-well plates with a layer of 10 mg/ml
Matrigel diluted with 1:1 (v/v) serum-free medium. The plates pre-coated with Matrigel
were then incubated at 37°C for 60 min. HUVEC suspensions were cultured in culture
medium with different concentrations of released Rg1, standard Rg1, or VEGF. The
plates were incubated for 8 h at 37°C. Tubular structures were dyed with calcein-AM,
photographed (100 ×), and examined using Image J software (US National Institutes of
Health, http://rsb.info.nih.gov/ij/). The percent of tube formation in each experimental
group was compared with tube formation in the control group.
Apoptosis determination by annexin V-FITC assay
In brief, 5 × 105 cells/well were seeded onto six-well culture plates. After 24 h of cell at-
tachment and 24 h of serum starvation, the cells were exposed to fresh medium with
different concentrations of released Rg1, standard Rg1, or VEGF. After 24 h of culture,
the cells were rinsed with PBS, trypsinized, and centrifuged for 5 min at 2,000 rpm.
The cells were then resuspended in 500 μl of Annexin V Binding Buffer, which was
provided in the Annexin V-FITC Kit (KeyGEN, Beijing, China). Next, 5 μl of annexin
V-FITC and 5 μl of propidium iodide (PI) were added to the test tube. The cells were
incubated at room temperature for 15 min and protected from light. The samples were
then analyzed with a BD FACScan analyzer.
Cell-cycle progression
Cells were seeded onto six-well culture plates at a density of 5 × 105 cells/well. After
24 h of cell attachment and 24 h of serum starvation, different concentrations of re-
leased Rg1, standard Rg1, or VEGF were added to the culture medium for 24 h. Both
floating and attached cells were collected and fixed in 500 μl of ice-cold 75% ethanol
overnight and washed three times in PBS. The cells were then treated with 100 μl of
RNase A at 37°C for 30 min, stained with 400 μl of PI at 4°C for 30 min, and stored in
the dark. The fluorescence of PI in HUVECs was measured using a BD FACScan
analyzer. The wavelength of laser excitation was set at 488 nm, with an emission wave-
length at 590 nm. In total, 20,000 cells were analyzed for each group. The percentages
of cells in the G0/G1 phase, S phase, and G2/M phase were counted using GraphPad
Prism 5.0 software (GraphPad Prism Software, San Diego, CA, US).
Immunocytofluorescence staining of VEGF
Immunocytofluorescence (ICF) staining was performed to demonstrate VEGF expres-
sion in HUVECs. HUVECs were first cultured in 24-well plates. After 24 h of cell at-
tachment, different concentrations of released Rg1, standard Rg1, or VEGF were added
to the culture medium for 24 h. The HUVECs were washed with PBS three times and
fixed with 4% chilled paraformaldehyde for 20 min. The HUVECs were washed three
times in PBS, followed by a blocking step using 5% bovine serum albumin (BSA) for
20 min. A mouse monoclonal anti-VEGF antibody was then added and incubated
overnight, followed by incubation with FITC-conjugated goat anti-mouse IgG sec-
ondary antibody for 1 h at room temperature in the dark. Additionally, the cell
nuclei were stained with DAPI for 30 min at room temperature in the dark. After
all of the steps, the cells were observed and photographed using a fluorescence
Zheng et al. BioMedical Engineering OnLine 2013, 12:134 Page 6 of 16
http://www.biomedical-engineering-online.com/content/12/1/134microscope (Leica, Germany). Images were acquired and processed using Image-
Pro Plus software [16].
Cell culture on CC-GMS scaffolds
Composite scaffolds for in vitro cell growth were sterilized by exposure to UV light for
30 min on each side. Aliquots of 20 μl of HUVECs were seeded onto CC-GMS scaf-
folds containing different concentrations of Rg1 or VEGF at a density of 5 × 104 cells
per scaffold. The scaffolds were left undisturbed in an incubator for 2 h at 37°C to
allow cell attachment, after which an additional 1 ml of low-FBS medium was added to
each well. The cells were cultured for 7 days, and the medium was changed every 3
days. Afterward, the scaffolds were first washed with PBS three times and then were
fixed in 4% paraformaldehyde overnight. After washing with PBS three times, the scaf-
folds were stained with 100 μg/ml DAPI for 30 min at 37°C, followed by FITC staining
for 20 min. The scaffolds were then photographed using a laser scanning confocal
microscope (Leica, Germany).
Statistical analysis
The data were expressed as the mean ± standard deviation (SD) and were analyzed by
one-way ANOVA and Tukey’s tests to determine the level of significance. A p value <
0.05 was considered to be significant, and p < 0.01 was considered to be highly
significant.
Results
Fabrication of GMSs and CC-GMS scaffolds
Figure 1 demonstrates the morphology of the GMSs and CC-GMS scaffolds. The GMSs
were round, with diameters between 10 and 50 μm (Additional file 1). The CC-GMS
scaffold demonstrated a three-dimensional porous structure with a pore size of
110 ± 12 μm and a porosity of 92% ± 0.4%. The diameter of the CC-GMS scaffolds
was approximately 2 cm, with a thickness of 2 ± 0.2 mm. The CC-GMS scaffold
possessed interconnected structures after the GMSs were distributed evenly. The degrad-
ation rate of GMS and CC-GMS scaffold were 21.67 ± 3.05 days and 23.33 ± 1.52 days
respectively.Figure 1 Scanning electron micrographs of GMSs and the CC-GMS scaffold. A-B: Scanning electron
micrographs of GMSs. C: Scanning electron micrographs of the CC-GMS scaffold. The average inner pore
size of the CC-GMS scaffold was 110 ± 12 μm, and the diameters of the GMSs were between 10 and 50 μm.
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The cumulative Rg1 released from the CC-GMS scaffold and the GMSs is shown in
Figure 2. Initial burst release was observed both from the CC-GMS scaffold and the
GMSs during the first day, followed by slow release for up to 7 days, followed by a lev-
eling off. The initial release of Rg1 (50, 100, or 200 μg) from the CC-GMS scaffold was
46%, 46.26%, and 46.5%, compared respectively with each total Rg1 dosage. The initial
release of Rg1 (50 μg) from the GMSs was 49.667%. Then the amount released from both
systems increased stably and slowly. After 7 days, the total release was 77.86%, 80.46%,
and 78.96%, respectively from the CC-GMS scaffold and 83.27% from the GMSs. As the
Rg1 loading content increased, the release rate increased correspondingly.
Effects of Rg1 on HUVEC proliferation
The loading of Rg1 into the CC-GMS scaffold may alter the activity of Rg1. In this
study, chemotactic activity was measured to examine the stability and activity of the
Rg1 that was released from the CC-GMS scaffold.
The effect of the released Rg1 on the proliferation of HUVECs was evaluated by XTT
assay. As shown in Figure 3, Rg1 increased the proliferation of HUVECs in a dose- and
time-dependent manner, with statistical significant proliferation observed at 50 μg/ml
and at a time point of 72 h, with proliferation in 267.59% of HUVECs. The proliferative
effect of 50 μg/ml released Rg1 was slightly lower than the effect of VEGF (290.401%)
or 50 μg/ml standard Rg1 (281.085%) but higher than the effect of 100 μg/ml released
Rg1 (247.955%).
Effect of Rg1 on HUVEC migration
The influence of the released Rg1 on HUVEC migration was determined by measuring
the number of migrated cells, as shown in Figure 4. Compared with the control group,Figure 2 Release of Rg1 from the CC-GMS scaffold and GMS. The effects of loading content on Rg1
release: (●) 50 μg, (■) 100 μg, and (▲) 200 μg of Rg1 in CC-GMS scaffolds and (▼) represent 50 μg Rg1
in GMS.
Figure 3 Effects of the released Rg1 on HUVEC proliferation. Cell proliferation was assessed using the
XTT assay after 12, 24, 48 or 72 h of treatment with different concentrations of released Rg1, 50 μg/ml
standard Rg1, or 20 ng/ml VEGF. The results are expressed as the percent of cell proliferation compared
with the control at 0 h. The data are expressed as the mean ± SD from three individual experiments.
*p < 0.05 compared with the control group.
Figure 4 Effect of the released Rg1 on HUVEC migration. Observation of the effect of the released Rg1
on HUVEC migration after 24 h using a Transwell culture insert. A: Control group (untreated); B: 0.1 μg/ml
released Rg1; C: 1 μg/ml released Rg1; D: 10 μg/ml released Rg1; E: 50 μg/ml released Rg1; F: 100 μg/ml
released Rg1; G: 50 μg/ml standard Rg1; and H: 20 ng/ml VEGF. I: The percentage increase in HUVEC migration
was compared with migration in the control group (untreated). Photographed by microscope at 200 × .The
data are expressed as the mean ± SD. Significant differences compared with controls are presented (*p < 0.05).
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HUVECs. Rg1 reached a maximum effect at a concentration of 50 μg/ml (Figure 4I).
When the concentration reached 100 μg/ml, the migrated cell number did not increase.
VEGF at 20 ng/ml had a 14.6% greater pro-migration effect than did 50 μg/ml Rg1.
Meanwhile, the released Rg1 at 50 μg/ml showed little decrease (11.1%) compared with
50 μg/ml standard Rg1. There was no statistical difference between the 50 μg/ml stand-
ard Rg1 group and the VEGF group regarding HUVEC migration.
Effect of Rg1 on Matrigel-induced tube formation
To test the effect of the released Rg1 on HUVEC tube formation, a Matrigel model was
used in this study. HUVECs did not form tubes, at least at a seeding density of 50,000
cells per well. As shown in Figure 5, the number of branching points was counted and
then compared with that of the control group. The released Rg1, the standard Rg1, and
VEGF all triggered significant increases in the number of elongated and robust tube-
like structures. The released Rg1 induced cell tube formation in a dose-dependent
manner, and the most effective concentration was 50 μg/ml. When the Rg1 concentra-
tion was above 1 μg/ml, the stimulation was found to be statistically significant com-
pared with that of the blank control (p < 0.05). The standard Rg1 group exhibited
6.18% lower activity than did the VEGF group. However, the remaining activity of
50 μg/ml released Rg1 remained approximately the same as that of standard Rg1.Figure 5 Effect of Rg1 on HUVEC tube formation. In total, 1 × 105 HUVECs were seeded on Matrigel-coated
48-well culture plates and treated with released Rg1, standard Rg1, or VEGF. After 8 h, tubular structures were
photographed (100 ×). A: Control group (untreated); B: 0.1 μg/ml released Rg1; C: 1 μg/ml released Rg1;
D: 10 μg/ml released Rg1; E: 50 μg/ml released Rg1; F: 100 μg/ml released Rg1; G: 50 μg/ml standard
Rg1; and H: 20 ng/ml VEGF. I: The percentage increase in tube formation was compared with tube
formation in the control group (untreated). Photographed by microscope at 100 ×. The data are expressed
as the mean ± SD. Significant differences compared with controls are presented (*p < 0.05).
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To determine the effect of the released Rg1 on the HUVECs’ cell cycle, a cell cycle ana-
lysis was performed. Incubation with either Rg1 or VEGF resulted in increased cell-
cycle progression (Figure 6). Rg1 significantly increased the number of HUVECs in the
proliferative phase (S and G2/M phases) and decreased the number in the resting phase
(G0/G1 phase) in a dose-dependent manner. The control group displayed a low per-
centage of proliferation (S phase, 12.78%, and G2/M phase, 2.84%), whereas the per-
centage of cells in the S phase increased to 30.23% and in the G2/M phase increased to
14.46% with 50 μg/ml Rg1 treatment. Compared with 1, 10 and 100 μg/ml Rg1 group,
50 μg/ml Rg1 group had statistical significant differences both in S phase and G2/M
phase. In the VEGF group, 30.94% of cells were in the S phase, and 17.69% were in the
G2/M phase. There was no statistical difference between 50 μg/ml Rg1 group and
VEGF group. The standard Rg1 group showed a similar effect as the 50 μg/ml released
Rg1 group, with 28.45% cells in the S phase and 18.02% in the G2/M phase. These data
suggest that Rg1 induces cell proliferation by increasing the proportion of cells in the S
and G2/M phases and that the released Rg1 did not lose its activity.
Annexin V-FITC/PI staining was used to determine the extent of HUVEC apoptosis.
As shown in Figure 7, the released Rg1 groups, the VEGF group, and the standard Rg1Figure 6 Cell cycle of HUVECs after 24 h of treatment, as detected by flow cytometry. A: Control
group (untreated); B: 0.1 μg/ml released Rg1; C: 1 μg/ml released Rg1; D: 10 μg/ml released Rg1; E: 50 μg/ml
released Rg1; F: 100 μg/ml released Rg1; G: 50 μg/ml standard Rg1; and H: 20 ng/ml VEGF. The percentage of
cells in the G0/G1, S, and G2/M phases are indicated on the upper right side. I: The percentage of cells residing
in the G0/G1, S, and G2/M phases. The data are expressed as the mean ± SD. Significant differences compared
with controls are presented (*p < 0.05).
Figure 7 Cell apoptosis of HUVECs after 24 h of treatment, as detected by flow cytometry. Representative
images of cell apoptosis. A: Control group (untreated); B: 0.1 μg/ml released Rg1; C: 1 μg/ml released Rg1;
D: 10 μg/ml released Rg1; E: 50 μg/ml released Rg1; F: 100 μg/ml released Rg1; G: 50 μg/ml standard Rg1;
and H: 20 ng/ml VEGF. The percentage of cells in each percentage are indicated on the upper right side.
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V-FITC- and PI-positive cells. These results demonstrate that Rg1 has little toxicity to-
ward HUVECs at the tested concentrations and that CC-GMS scaffold degradation did
not increase the toxicity of the released Rg1.
Effect on VEGF expression
The expression of VEGF, which normally creates new blood vessels, was further
assessed by an ICF assay after 24 h of incubation. As shown in Figure 8, both Rg1 and
VEGF caused an increase in VEGF expression, and the VEGF expression of HUVECs
increased along with the increase in the released Rg1 concentration. In the 50 μg/ml
Rg1 group, the VEGF expression was most significant, at approximately 4.18 times
of the expression in the control group. The VEGF expression of the VEGF group
and the standard Rg1 group was 4.38 and 4.20 times of the control group’s expres-
sion, respectively. Compared with standard Rg1, the released Rg1 at 50 μg/ml
showed a similar effect on VEGF expression. These findings demonstrated that Rg1
can induce VEGF expression, which is of great importance in the early stage of
angiogenesis.
HUVEC proliferation on CC-GMS scaffold
Figure 9 shows laser scanning confocal microscopy (LSCM) images of proliferated
HUVECs on the Rg1-loaded CC-GMS scaffold after 7 days of cultivation. The scaffold
was brittle in its dried state but provided good malleability after being wetted with cul-
ture medium. The HUVECs were well attached and proliferated in a multilayered phase
over the CC-GMS scaffold. Compared with proliferation in the vehicle group, enhanced
HUVEC proliferation was observed within both the Rg1- and the VEGF-loaded CC-GMS
scaffolds. Moreover, after 7 days of cultivation, the 50 μg/ml Rg1 group showed 18.84%
more HUVEC proliferation than did the VEGF group. These results demonstrated that
the porous CC-GMS scaffold could be utilized as a skin tissue substitute with the ability
to regulate Rg1 release and the potential to increase cellular growth.
Figure 8 VEGF expression of in vitro-cultured HUVECs. ICF analysis of the effect of the released Rg1 on
the VEGF expression of HUVECs after 24 h of treatment. A: Control group (untreated); B: 0.1 μg/ml released
Rg1; C: 1 μg/ml released Rg1; D: 10 μg/ml released Rg1; E: 50 μg/ml released Rg1; F: 100 μg/ml released
Rg1; G: 50 μg/ml standard Rg1; and H: 20 ng/ml VEGF. I: The relative counts of VEGF-positive cells,
as determined by ICF staining for VEGF. IOD: Integral optical density. Significant differences compared
with controls are presented (*p < 0.05). Photographed by microscope at 200 × .
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VEGF is an endothelial cell-specific mitogen and an angiogenesis inducer. VEGF pro-
motes the growth of vascular endothelial cells from the arteries, veins, and lymphatics
[17]. VEGF is also a survival factor for endothelial cells, as it prevents the endothelial
apoptosis induced by serum starvation. This prevention is achieved by mediating the
phosphatidylinositol 3-kinase (PI3K)/Akt pathway [18] and inducing expression of the
anti-apoptotic proteins Bcl-2, A1, XIAP, and survivin in endothelial cells [19,20]. As a
functional ligand of the glucocorticoid receptor (GR), Rg1 has been shown to increase
the phosphorylation of GR and the activities of PI3K, Akt/protein kinase B, and eNOS
in HUVECs [21]. PI3K/Akt signaling has been found to be significantly important in
HUVEC growth, survival, protein synthesis, and angiogenesis [22]. Consistent with this
pathway, similar to VEGF, standard Rg1 at 50 μg/ml stimulated significant HUVEC
proliferation, migration, and tube formation, with increases of 267.59% (72 h), 186.42%,
and 252.73%, respectively, compared with the vehicle control group. This finding is in
accordance with reports that Rg1 promotes HUVEC proliferation, migration, and tube
formation [23].
Moreover, as expected, both Rg1 and VEGF promoted HUVEC transition from G0/G1
to G2/M. Treatment of HUVECs with standard Rg1 or VEGF for 24 h induced a signifi-
cant percentage of cells to enter the S and G2/M phases (28.45% and 30.94%, respectively,
in the S phase and 18.02% and 17.69%, respectively, in the G2/M phase) compared with
Figure 9 Observation of cell attachment to and proliferation in CC-GMS scaffolds by LSCM. After 7
days of cell culture in CC-GMS scaffolds, the scaffolds and cell nuclei were stained with FITC and DAPI, respectively,
and observed by LSCM. A: Control group (untreated); B: 0.1 μg/ml released Rg1; C: 1 μg/ml released
Rg1; D: 10 μg/ml released Rg1; E: 50 μg/ml released Rg1; F: 100 μg/ml released Rg1; and G: 20 ng/ml VEGF.
H: The relative counts of cells attached to the CC-GMS scaffold. Green and blue represent the CC-GMS scaffold
and cell nuclei, respectively, photographed by a microscope at 200 ×. Significant differences compared with
controls are presented (*p < 0.05).
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after 24 h of treatment, Rg1 did not increase the proportion of apoptotic cells (Figure 7),
and all of the groups were similar. In support of our data, it has been reported that the ac-
tivation of PI3K and PKB leads to FOXO3a phosphorylation and sequestration in the
cytoplasm, thereby reducing growth arrest and DNA damage-inducible 45a expression,
thus activating G2/M progression [24].
Because VEGF is known to be a key activator of angiogenesis, we examined whether
Rg1 could upregulate VEGF production. We found that VEGF production was signifi-
cantly elevated in response to Rg1 stimulation, as determined by an ICF assay (Figure 8).
In support of our data, Rg1 has been reported to be a potent stimulator of VEGF ex-
pression in HUVECs, and importantly, this induction is mediated through a PI3K/Akt-
and β-catenin/T-cell factor-dependent pathway via the GR [25]. These results suggest
that Rg1 promotes HUVEC survival, proliferation, migration, tube formation, cell-cycle
progression, and VEGF expression and that these effects are dependent on the PI3K/
Akt pathway.
In this study, GMSs were used as carriers. The GMS release rate could be controlled
by various cross-linking conditions, including the cross-linking agent type, density, and
reaction period [26]. The cross-linking conditions were 1% glutaraldehyde solution at
37°C for 2 h. Under these conditions, the initial burst release of Rg1 was approximately
46% (Figure 2). Rapid release at the initial step and maintenance of a proper concentra-
tion at the local site are favorable for bioreagent delivery [27]. The sustained release test
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Rg1-impregnated CC-GMS scaffold. Moreover, the release rate of Rg1 from the CC-
GMS scaffold varied with the loading content. The release rate increased proportionally
as the loading content increased. An initial Rg1 burst release may properly induce
HUVEC attachment and proliferation, and the following steady release of Rg1 effi-
ciently stimulates HUVEC migration and tube formation, thus leading to vascular
structure formation. Incorporation of GMSs into the CC-GMS scaffold was thus re-
quired to attain steady Rg1 release.
Ginsenoside Rg1 consists of a gonane steroid nucleus and has 17 carbon atoms ar-
ranged in four rings [28]. The specific chemical structure of Rg1 consists of a high de-
gree of ring structure, which makes its flexibility very limited. The ring structure is
known to be inherently stable [29]. The Rg1 released from the CC-GMS scaffold
showed nearly the same tube formation activity (96.06%) as did the standard Rg1 solu-
tion. This result revealed that the Rg1 in the CC-GMS scaffold maintained its biological
activity and that the fabrication procedure did not affect the stability of Rg1. In
addition, the effect of the Rg1 released from the CC-GMS scaffold showed that Rg1 ex-
erts its effect in a dose-dependent manner. Additionally, the concentration of Rg1
(50 μg/ml) used in this study is the optimal stimulatory dose for HUVECs, with responses
slightly decreasing at higher doses. This phenomenon may be due to the effect of the
cytotoxicity of ginsenoside Rg1 when the concentration is increased to 100 μg/ml.
Additionally, the above results revealed that the release rate of Rg1 can be con-
trolled by varying the initial loading content of Rg1 to attain optimal therapeutic
efficacy for wound tissue regeneration.
The Rg1-loaded CC-GMS scaffold induced significantly high cell attachment and pro-
liferation, which indicated good cellular adaptability. Steady stimulation by the Rg1
from the CC-GMS scaffold might cause rapid cell proliferation within the scaffold. At 7
days after HUVEC culture on the CC-GMS scaffold, the Rg1-mediated effect on
HUVEC attachment was approximately 18.84% higher than the effect of VEGF
(Figure 9). These results indicated that the chemical stability of Rg1 was significantly bet-
ter than that of VEGF. It is known that proteins are often unstable outside their native en-
vironments. The occurrence of protein denaturation may be attributed to a variety of
factors, such as pH, buffer species, and temperature. The half-life of VEGF was less than
10 h. In contrast, the activities of Rg1 remained approximately the same. These results
demonstrated that the CC-GMS scaffold can be utilized as a skin tissue substitute mater-
ial with the ability to regulate Rg1 release and the potential to stimulate cellular growth. It
is anticipated that different types of cells will freely migrate into Rg1-loaded CC-GMS
scaffolds when applied to a skin defect to improve skin tissue angiogenesis and regener-
ation efficacy.
Conclusion
Rg1-loaded CC-GMS scaffolds may control Rg1 release, serve as a physical scaffold
for cell proliferation, and promote angiogenesis. The Rg1 in the scaffold retained
its biological activity, and the Rg1 released from the CC-GMS scaffold enhanced
HUVEC proliferation, migration, tube formation, cell-cycle progression, and VEGF
expression. The Rg1-loaded CC-GMS scaffold might be a valuable modality in skin
tissue engineering-based angiogenesis and regenerative therapy.
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